

SERUM EXCHANGE #590 AUGUST 14, 2023

Sera	1357 - 1361
------	-------------

The results for **Serum Exchange 590 (sera 1357 - 1361)**, are summarized in Tables 1 – 7 and individual laboratory results by method are listed in

Tables 8 - 21. Sera strongly positive to A2, B27, B35, B49, DQ3 (DQ7, DQ8, DQ9), and DR51 were examined in this study.

1357	method	#labs	B27	B2708	B2705	B42	B67	B7	B81	B55	B56	B54	B8101	B60	B61	B82	B8201	B73	B57	B58	B63	B13	B47	A25	A2	A32	
class I	AHG	1	no consensus																								
	C1q	2	100%			100%	100%	100%	100%	100%	50%			50%	50%	50%											
	PRA	5	80%	20%		80%	80%	80%	80%	80%	80%	80%		60%	60%	40%		40%	60%	60%	60%	60%	60%	60%	60%	60%	
	SAB	25	100%	32%	16%	100%	100%	100%	100%	100%	100%	100%	12%	96%	92%	96%	12%	100%	100%	100%	100%	96%	96%	100%	96%	96%	
1357	method	#labs	Cw 2	B48	B8	A66	A6602	A24	A2403	A23	Cw 17	B41	A203	B64	B703	B18	B22	Cw 7	A10	B15	B17	Bw 6	Cw 14	A19	B40	Bw 4	Cw 12
	PRA	5	20%	60%	20%	40%		20%		20%		40%	20%		20%	20%	20%	20%									
	SAB	25	96%	92%	84%	80%	44%	72%	8%	68%	68%	56%	28%	20%	16%	8%	8%		8%	8%	8%	8%	8%	4%	4%	4%	4%

1357	method	#labs	NEG	DPw 1
class II	C1q	1	NT	
	PRA	5	100%	
	SAB	17	88%	12%

Serum 1357. Strong anti-B7 (24212), -B27 (20512), -B22 (B55) (18517), and -B40 (B61) (17167) reactivity was detected in this sample by all methods. Each were assigned by $\geq 90\%$ of SAB labs. Additional reactivity to A25 (11846), A2 (3747), A32 (8348), as well as reactivity to a number of 7C and

5C specificities was reported by various methods. Allele specific B*27:08 (12521), B*27:05 (12109), and A*66:02 (15511) reactivity was also reported by a number of labs.

This sample was reported as negative for class II by PRA and SAB.

*(median MFI by SAB)

1358	method	#labs	A2	A68	A69	B57	B58	B49	B51	B53	B63	B77	B38	B44	B59					
class I	AHG	1	no consensus																	
	C1q	2	100%	100%	100%	100%	100%													
	PRA	5	80%	80%	60%	60%	60%	60%	60%	60%	60%	40%	60%	60%	60%					
	SAB	26	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%					
1358	method	#labs	A23	A24	A2403	A25	A32	B37	B52	B13	B47	B27	B2705	Bw 4	A203	B39	B67	B62	B15	
	PRA	5	60%	60%	20%	60%	60%	60%	60%	60%	60%	60%			20%	20%	20%			
	SAB	26	100%	96%	35%	100%	96%	96%	96%	92%	92%	88%	31%	42%	35%			15%	12%	
1358	method	#labs	Cw 7	A10	A19	A28	A9	B12	B17	B21	B5	Cw 4	A10C	A2C	A66	A6602	B16	B7	Cw 2	
	SAB	26	12%	8%	8%	8%	8%	8%	8%	8%	8%	8%	4%	4%	4%	4%	4%	4%	4%	

1358	method	#labs	DR7	DQ7	DQ8	DQ9	DQ3	DR12	DR9	DQ6	DQ4	DR52	DQ2	DQA1*02	DQA1*03	
class II	C1q	1	no consensus													
	PRA	5	80%	80%	80%	80%		60%	60%	60%	40%	40%	40%			
	SAB	25	100%	100%	100%	100%	12%	100%	100%	96%	92%	92%	76%	48%	48%	
1358	method	#labs	DQA1*04	DQA1*05	DQA1*06	DQA1*01	DR53	DR17	DR18	DR13	DR11	DR51	DQ1	DR5	DR14	
	PRA	5					20%	20%	20%	20%	20%	20%				
	SAB	25	32%	32%	32%	20%	4%						8%	8%	4%	

Serum 1358. This sample was reported as strongly positive for A2 (20173), A68 (18810), A69 (19770), B57 (16723), and B58 (17496) by all methods. Additional anti-B38 (12121), -B44 (6589), -A23 (14954), -A24 (15164), -A25 (13166), -A32 (15766), -B37 (9670) reactivity, along with reactivity to a number of 5C and 7C specificities was detected by PRA and SAB. Allele specific A*24:03 (8517) and B*27:05 (6133) reactivity was also reported by labs.

Strong class II reactivity was detected in this sample, with C1q, PRA, and

SAB reporting positivity to DR7 (18711), DQ7 (15674), DQ8 (16138), and DQ9 (15837). Each were reported by 100% of SAB labs. Reactivity to a number of additional DR and DQ specificities, including DR12 (8179), DR9 (9462), DR52 (9567), DQ6 (3993), DQ4 (5556), and DQ2 (5038) was reported by PRA and SAB. Strong anti-DQA1*02 (11488), DQA1*03 (10201), DQA1*05 (14541), DQA1*06 (13498) reactivity, along with allele specific DRB3*01:01 and DRB3*03:01 reactivity, was also reported by SAB labs.

*(median MFI by SAB)

1359	method	#labs	A32	B49	B51	B52	B53	B57	B58	B63	B77	B37	B44	B47	B38	B59	B27	B2705	B2708	A25	A23	A24	A2403	B35	B50	B62
class II	AHG	1	no consensus																							
	C1q	2	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%	50%									
	PRA	5	80%	80%	80%	80%	80%	80%	80%	80%	50%	50%	50%	50%	50%	50%	50%			80%	80%	80%	20%	50%	50%	50%
	SAB	26	100%	100%	100%	96%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	92%	27%	4%	100%	100%	92%	31%	92%	92%	92%

1359	method	#labs	B71	B72	B75	B56	B78	B7801	B13	Bw 4	B64	B65	Cw 17	Cw 2	Cw 4	Cw 18	Cw 15	Cw 6	Cw 5	B46	Cw 10	Cw 9	Cw 16	B81	B8101	B48
	C1q	2								50%																
	PRA	5	50%	50%	50%	40%	40%		40%		20%	20%	20%	40%	20%	40%								20%		
	SAB	26	92%	92%	88%	92%	81%	15%	65%	35%			92%	92%	88%	85%	92%	77%	65%	35%	35%	27%	19%	4%	4%	23%

1359	method	#labs	B4005	B7	B15	B18	A10	A19	A9	B12	B45	B16	B17	B21	B5	B76	B40	B60	B61	B55	B41	B67	Cw 1	Cw 14	Cw 3	Cw 403	Cw 8	
	SAB	26	19%	19%	15%	15%	8%	8%	8%	8%	4%	8%	8%	8%	8%	4%	8%	8%	8%	4%	4%	4%	4%	8%	4%	4%	4%	4%

1359	method	#labs	DQ7	DQ8	DQ9	DQ3	DR4	DR1	DR53	DR11	DP18	DP28	DPw 2	DPw 4	DP402	DR14
class II	C1q	1	NT													
	PRA	4	80%	80%	80%	20%	60%	80%	60%	60%	20%	20%				
	SAB	21	100%	96%	100%	12%	96%	92%	92%	84%	80%	80%	84%	72%	32%	64%

1359	method	#labs	DQ4	DP10	DQA1*05	DQA1*03	DR9	DP17	DP9	DP14	DPw 6	DR10	DR7	DR103	DR12	DR15
	PRA	4					20%	20%	20%	20%	20%	20%	20%	20%	20%	20%
	SAB	21	60%	52%	56%	40%	36%	44%	44%	40%	40%	8%	4%			

1359	method	#labs	DR16	DR51	DR8	DP20	DQ2	DQA1*06	DQA1*02	DPA1*04	DPA1*01	DPA1*02	DP105	DQA1*04	DPA1*03	DR5
	PRA	4	20%	20%	20%											
	SAB	21				28%	28%	28%	20%	20%	16%	12%	8%	8%	4%	4%

Serum 1359. For this sample, reactivity to A32 (18113), B27 (15670), B37 (15571), B44 (15817), B49 (19346), B51 (17121), B52 (14809), B57 (17772), and B58 (16586) was reported by all methods. Additional anti-B37 (15571), -B44 (15817), -B47 (14347), -B38 (17024), -A25 (12983), -A23 (13586), -A24 (5034) reactivity, as well as reactivity to a number of 5C and 7C specificities was reported by various methods. Allele specific B*27:05 (15426) and

A*24:03 (3371) reactivity was also reported by some labs.

Strong class II reactivity was detected in this sample, with PRA and SAB reporting reactivity to a number of DQ and DR specificities including, DQ7 (8457), DQ8 (8573), DQ9 (8246), DR4 (11425), DR1 (6771), and DR53 (4725). Allele specific DRB1*14:02 reactivity was also reported by 4 labs.

*(median MFI by SAB)

1360	method	#labs	A1	A11	A1101	A1102	A36	B7	A24	A2403	B81	B8101	A3	B27	B2708	B2705	B48	B61	B60	B13	A80	
class I	AHG	1	NT																			
	C1q	2	NT																			
	PRA	5	80%	80%			80%	60%	20%		20%		20%	20%			20%	20%	20%			
	SAB	26	92%	92%	27%	23%	92%	96%	88%	27%	88%	15%	73%	73%	19%	15%	62%	62%	58%	69%	58%	
1360	method	#labs	B42	B67	B73	A26	A31	A34	A43	A33	A66	A6601	A6602	B40	B8	A25	A29	A30	B46	B47	B55	Cw 6
	SAB	26	27%	27%	27%	19%	15%	15%	15%	8%	8%	8%	4%	8%	8%	4%	4%	4%	4%	4%	4%	4%

1360	method	#labs	DR51	DR103	DR1	DR9	DR15	DR16	DR10	DR53	DQ2	DQA1*05	DQA1*04	DR2	DQA1*02	DQA1*03
class II	C1q	1	no consensus													
	PRA	5	80%	80%	80%	80%	80%	80%	80%	80%						
	SAB	24	100%	96%	100%	100%	100%	96%	96%	96%	83%	25%	8%	8%	4%	4%

Serum 1360. Anti-A1 (5709), -A11 (2721), -A36 (4348), and -B7 (3343) reactivity was reported in this sample by PRA and > 90% of SAB labs. Additional reactivity to a number of other 1C and 10C specificities was also reported, including reactivity to A24 (2821), B81 (2964), and B27 (2375).

This sample was also positive for class II, with PRA and > 90% of SAB labs reporting reactivity to DR1 (4120), DR51 (16525), DR103 (6226), DR1 (4120), DR9 (4408), DR15 (4064), DR16 (3045), DR10 (2284), and DR53 (3321).

*(median MFI by SAB)

1361	method	#labs	B35	B51	B53	B49	B50	B21	B58	B62	B63	B71	B72	B70	B75	B78	B7801	B56	Cw 5	Cw 6	Cw 15	Cw 4	Cw 9	Cw 10	Cw 1	
class I	AHG	1	no consensus																							
	C1q	1	100%	100%	100%	50%	50%		50%	100%	50%	100%	50%		50%	100%		50%	100%	100%	100%	50%	50%	50%	50%	
	PRA	5	80%	80%	80%	60%	60%	20%	60%	60%	60%	60%	60%	20%	60%	80%		40%	20%	20%	20%	20%	20%	20%	20%	
	SAB	26	100%	100%	100%	100%	100%	8%	100%	100%	100%	100%	96%	8%	100%	96%	23%	100%	100%	100%	96%	100%	100%	100%	96%	
1361	method	#labs	Cw 14	Cw 18	B18	B46	B57	B17	B77	Cw 2	Cw 17	Cw 16	B37	B52	A 1	A 11	A1101	A1102	A 24	A2403	A 3	B13	A36	A 80	B76	
	C1q	1	50%	100%								50%														
	PRA	5	20%	20%	80%	60%	60%	20%	60%	20%	20%		60%	80%	60%	60%			60%	20%	60%	60%	60%	60%	40%	
	SAB	26	92%	92%	100%	100%	100%	8%	100%	100%	92%	23%	96%	96%	92%	92%	27%	27%	92%	27%	92%	92%	88%	88%	85%	
1361	method	#labs	B54	B27	B2708	B2705	B44	B45	B41	B60	B61	B55	B82	B8201	Cw 12	B59	A43	A25	A32	A26	A23	A66	A6601	A6602	A74	
	PRA	5	40%	40%			20%	20%	20%	40%	20%	20%	20%					40%	20%	20%	20%	20%				
	SAB	26	85%	81%	19%	15%	81%	81%	81%	81%	62%	73%	50%	15%	73%	50%	81%	62%	46%	35%	31%	31%	15%	8%	31%	
1361	method	#labs	A33	A34	B47	B15	B7	A29	A30	Cw 7	A31	B39	B3901	B4005	B48	Bw 4	Cw 3	B22	B5	B5C	Bw 6	B14	B40			
	PRA	5	20%	20%	20%	20%																				
	SAB	26	19%	15%	19%	12%	31%	27%	27%	23%	19%	19%	4%	19%	19%	12%	12%	8%	8%	8%	8%	4%	4%			

1361	method	#labs	DR15	DR16	DR51	DQ6	DQ5	DR9	DPw 1	DPw 5	DP11	DP14	DP13	DR103	DR10
class II	C1q	1	NT												
	PRA	5	80%	80%	80%	80%	40%	40%	20%	20%	20%	20%	20%	20%	20%
	SAB	24	100%	100%	100%	100%	88%	92%	79%	71%	50%	50%	46%	46%	42%
1361	method	#labs	DR1	DP19	DPw 3	DP9	DPw 6	DP17	DQ9	DR53	DQA1*01	DP10	DP20	DPA1*02	DPA1*03
	PRA	5	20%	20%					20%						
	SAB	24	38%	42%	54%	50%	46%	42%		33%	33%	33%	29%	25%	13%
1361	method	#labs	DP107	DP26	DP30	DP31	DP85	DQ1	DQ4	DR2	DR6	DR13	DR52	DPA1*01	DQA1*03
	SAB	24	8%	8%	8%	8%	8%	8%	8%	8%	4%	4%	4%	4%	4%

Serum 1361. Strong reactivity to B35 (19859), B49 (17606), B51 (19929), B53 (19337), B71 (17141), B72 (17720), Cw4 (17159), Cw6 (19379), Cw10 (13269), and Cw15 (18864) was reported by all methods. In addition, reactivity to B18 (15117), B37 (14291), as well as reactivity to a number of 1C, 5C, 7C, and C-locus specificities was reported by labs.

PRA and SAB labs also reported class II reactivity in this sample, with > 90% of SAB labs reporting reactivity to DR15 (7201), DR16 (3501), DR51 (3795), DQ6 (4258), and DR9 (2256). Reactivity to a number of DP specificities was also reported by PRA and SAB, including DP1 (3326), DP5 (2431), DP11 (1685), and DP14 (1802).

*(median MFI by SAB)

NEXT MAILING DATE: October 4, 2023

Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed